C4 Therapeutics Inc. (C4T) has announced the pricing of an underwritten offering, raising $125 million in upfront proceeds through the sale of 21,895,000 shares of its common stock and pre-funded warrants to purchase an additional 28,713,500 shares. Each share and pre-funded warrant is accompanied by a Class A Warrant and a Class B Warrant, each exercisable at $2.22 per share. The offering was led by RA Capital Management with participation from existing shareholders including OrbiMed, Soleus Capital, Lynx1 Capital Management, and Bain Capital Life Sciences. If all accompanying warrants are exercised, C4T could receive up to $349.7 million in total gross proceeds. The funds are intended to support ongoing and planned clinical trials of cemsidomide, other R&D activities, and general corporate purposes. Jefferies, TD Cowen, and Evercore ISI are acting as book-running managers for the offering.